BioXcel Therapeutics Inc (BTAI)
2.705
-0.26
(-8.92%)
USD |
NASDAQ |
Apr 24, 16:00
2.705
0.00 (0.00%)
After-Hours: 20:00
BioXcel Therapeutics Gross Profit Margin (Quarterly): -89.89% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -89.89% |
| September 30, 2023 | -50.15% |
| June 30, 2023 | 94.31% |
| Date | Value |
|---|---|
| March 31, 2023 | 95.63% |
| December 31, 2022 | 96.22% |
| September 30, 2022 | 91.97% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-89.89%
Minimum
Dec 2023
96.22%
Maximum
Dec 2022
39.68%
Average
93.14%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Synlogic Inc | -- |
| Cormedix Inc | -- |
| Bristol-Myers Squibb Co | 76.08% |
| Verastem Inc | -- |
| Ocular Therapeutix Inc | 90.64% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -2.32K% |
| Return on Assets | -127.9% |
| Return on Invested Capital | -171.1% |
| Profit Margin (Quarterly) | -5.92K% |
| Operating Margin (Quarterly) | -5.29K% |
| Return on Net Operating Assets | -2.33K% |